Financial Performance - Net profit attributable to shareholders decreased by 60.95% to CNY 11,425,729.13 for the year-to-date period[6] - Operating revenue declined by 3.68% to CNY 160,468,502.61 for the year-to-date period[6] - Basic and diluted earnings per share decreased by 61.11% to CNY 0.14[7] - The company reported a significant decrease in net profit after deducting non-recurring gains and losses, down 71.64% to CNY 6,719,997.90[6] - Total operating revenue for the third quarter was ¥59,391,157.16, a decrease of 3.5% compared to ¥61,781,770.47 in the same period last year[30] - Net profit for the third quarter was ¥23,897.49, significantly down from ¥15,579,365.46 in the same period last year[32] - The company reported a total profit of ¥2,781,264.69, down from ¥15,335,414.57 in the previous year[31] - Basic earnings per share for the quarter were ¥0.0015, compared to ¥0.19 in the same period last year[33] - Operating profit for the third quarter was ¥3,012,634.95, down from ¥15,335,414.54 year-over-year[31] Assets and Liabilities - Total assets increased by 3.80% to CNY 650,303,080.92 compared to the end of the previous year[6] - Current assets decreased to CNY 386,378,619.26 from CNY 391,307,108.99, a decline of about 1.8%[22] - Total liabilities rose to CNY 221,388,346.50 from CNY 229,010,521.51, a decrease of approximately 3.3%[28] - Total equity increased to CNY 420,154,736.98 from CNY 413,418,499.62, reflecting a growth of about 1.8%[28] - Non-current assets totaled CNY 263,924,461.66, up from CNY 235,195,596.75, indicating an increase of approximately 12.2%[23] Cash Flow - Cash flow from operating activities showed a significant improvement, with a net cash flow of CNY -833,688.41 compared to CNY -51,170,428.66 in the previous year[6] - Cash inflow from operating activities for the first nine months of 2018 was CNY 220,768,040.26, up from CNY 172,530,713.97 year-over-year[39] - Cash inflow from investment activities totaled CNY 182,165,220.84, compared to CNY 131,179,907.24 in the same period last year[40] - The net cash flow from investment activities was CNY 21,458,932.08, a recovery from negative CNY 48,671,007.24 in the previous year[40] - Cash inflow from financing activities was CNY 99,966,274.00, slightly up from CNY 93,111,325.00 year-over-year[40] - The net cash flow from financing activities was CNY 14,166,924.63, improving from negative CNY 73,946,498.82 in the previous year[40] Shareholder Information - The number of shareholders reached 5,034, with the largest shareholder holding 14.90% of the shares[9] Government Subsidies - The company received government subsidies totaling CNY 4,303,033.92 for the year-to-date period, which are closely related to its normal business operations[8] Inventory and Receivables - Inventory increased by 12.0586 million yuan, up 99.08%, mainly due to project stocking and costs of unfinished projects[11] - Accounts receivable increased to CNY 208,488,036.68 from CNY 197,043,588.93, reflecting a growth of about 5.5%[22] - Other receivables increased by 13.3321 million yuan, up 133.85%, primarily due to the intention payment for acquiring a stake in Dacheng Medical Investment Co., Ltd. paid to Zhejiang Xinhhe Industrial Group Co., Ltd.[11] Research and Development - Research and development expenses were ¥12,692,948.48, a slight decrease from ¥13,107,039.34 year-over-year[31] Future Plans - The company plans to continue focusing on market expansion and new product development to drive future growth[30]

Financial Performance - The company's operating revenue for the first half of 2018 was ¥101,077,345.45, a decrease of 3.57% compared to ¥104,818,261.42 in the same period last year[21]. - The net profit attributable to shareholders for the first half of 2018 was ¥11,305,565.45, down 17.36% from ¥13,680,164.93 in the previous year[21]. - The net profit attributable to shareholders after deducting non-recurring gains and losses decreased by 30.97% to ¥7,928,193.80 from ¥11,485,817.27 year-on-year[21]. - The basic earnings per share for the first half of 2018 was ¥0.14, down 17.65% from ¥0.17 in the same period last year[22]. - The company achieved operating revenue of CNY 101.08 million, a decrease of 3.57% compared to the same period last year[51]. - Net profit attributable to the listed company was CNY 11.31 million, down 17.36% year-on-year[51]. - The total profit for the current period is ¥9,002,514.60, down 45.0% from ¥16,401,880.65 in the previous period[115]. - The comprehensive income for the current period amounted to 11,305,565.45 RMB, reflecting a significant change in the company's financial performance[129]. Cash Flow - The company's cash flow from operating activities showed a significant improvement, with a net cash flow of -¥25,320,203.30 compared to -¥46,291,122.56 in the same period last year[21]. - The company reported a net cash flow from investment activities of CNY 38.47 million, a significant improvement from the previous year's negative cash flow[56]. - The company's cash flow from operating activities improved significantly, with a net cash flow of CNY -25.32 million compared to CNY -46.29 million in the previous year[54]. - Operating cash inflow totaled CNY 121,002,993.84, an increase from CNY 106,464,092.53 in the previous period, reflecting a growth of approximately 13.6%[122]. - The net cash increase for the period was CNY 6,169,370.58, contrasting with a net decrease of CNY -183,756,470.99 in the prior period[123]. Assets and Liabilities - The company's total assets at the end of the reporting period were ¥612,601,852.43, a decrease of 2.22% from ¥626,502,705.74 at the end of the previous year[21]. - The total assets of the wholly-owned subsidiary, Suzhou Mediston Investment Management Co., Ltd., were RMB 0.00 million as of the reporting period end[64]. - The total liabilities decreased from CNY 229,010,521.51 to CNY 216,946,927.49, a decline of about 5.4%[112]. - Owner's equity increased from CNY 413,418,499.62 to CNY 418,055,326.83, an increase of approximately 1.6%[112]. - The total equity at the end of the reporting period was 431,911,837.33 RMB, which includes various components such as capital reserves and surplus reserves[131]. Research and Development - Research and development expenses increased by 40.12% to CNY 27.96 million, reflecting the company's commitment to innovation[54]. - The company emphasizes the integration of IT technology with medical knowledge, focusing on continuous R&D to provide effective support for healthcare institutions and professionals[45]. - The company is committed to developing intelligent medical decision-making support through data analysis and mining[29]. - The company aims to enhance its technological capabilities through ongoing research and development initiatives[137]. Market Position and Strategy - The company operates in the medical information technology service industry, specifically in the healthcare application software sector[35]. - The company has established a comprehensive customer service system, covering over 1,300 medical institutions across 32 provinces by June 2018[29]. - The company has established its clinical management information system products in over 1,300 medical institutions across 32 provinces, achieving a leading market position in the clinical informationization sector[40]. - The company has over 400 representative clients in top-tier hospitals, including major institutions like PLA 301 Hospital and Shanghai Ruijin Hospital, enhancing its market reputation and customer base[43]. - The company plans to expand its market presence and invest in new product development to drive future growth[137]. Risks and Compliance - The report includes a risk statement indicating that forward-looking statements do not constitute a commitment to investors, highlighting potential investment risks[5]. - The company faces risks related to seasonal fluctuations in business operations, with revenue and net profit typically lower in the first two quarters of the year[68]. - The company recognizes the risk of increased bad debt provisions due to high accounts receivable, which could adversely affect financial performance[67]. - The company has committed to minimizing and regulating related party transactions, ensuring fairness and transparency in any unavoidable transactions[79]. - The company has not experienced any technology leakage or infringement incidents during the reporting period, but acknowledges the potential risks associated with core technology[70]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 5,292[94]. - The top ten shareholders hold a total of 56,000,000 shares, representing 69.25% of the total shares[97]. - The largest shareholder, Weng Kang, holds 13,728,000 shares, accounting for 16.96% of the total shares, with 12,000,000 shares pledged[97]. - The company has committed to stabilizing its stock price for three years following its IPO, with specific measures in place for compliance[81]. - The company held one shareholders' meeting during the reporting period, which complied with all legal and regulatory requirements[74]. Stock Incentive Plans - The company has a stock incentive plan that granted 920,000 stock options at an exercise price of 60.68 CNY per share and 929,300 restricted shares at a price of 30.25 CNY per share[11]. - The company plans to repurchase and cancel 1.57 million stock options and 28.777 million restricted stocks, with a repurchase price of 30.25 CNY per share[84]. - The total estimated cost for the stock option and restricted stock incentive plan is approximately 9.2605 million yuan, with annual allocations of 1.8622 million yuan in 2017, 3.7244 million yuan in 2018, 2.7680 million yuan in 2019, and 905.8 thousand yuan in 2020[86]. Accounting and Financial Reporting - The financial report has been confirmed by the company's management as true, accurate, and complete, with no significant omissions[7]. - The company adheres to the accounting standards set by the Ministry of Finance, ensuring that its financial reports accurately reflect its financial status and operational results[151]. - The company’s financial statements are prepared based on the going concern principle, indicating a sustainable operational capability for at least 12 months from the reporting date[149]. - The company recognizes impairment losses for financial assets when objective evidence indicates a decline in value, with potential reversals if conditions improve[188].

Financial Performance - Operating revenue increased by 9.98% to CNY 36,379,413.40 year-on-year[6] - Net profit attributable to shareholders was a loss of CNY 7,121,798.25, compared to a loss of CNY 4,477,171.76 in the same period last year[6] - Total revenue for Q1 2018 was CNY 36,379,413.40, an increase of 6.98% from CNY 33,076,790.86 in the previous year[32] - Net loss for Q1 2018 was CNY 4,907,314.78, compared to a net loss of CNY 3,165,002.47 in Q1 2017, representing a deterioration of 55%[33] - The company reported a net profit of -774,704.04 RMB for Q1 2018, compared to -1,659,957.00 RMB in the same period last year, indicating an improvement of approximately 53.4% year-over-year[36] Asset Management - Total assets decreased by 4.05% to CNY 601,125,235.76 compared to the end of the previous year[6] - Cash and cash equivalents increased by 57.78% to CNY 46,389,900.00, mainly due to the redemption of financial products and structured deposits[12] - Accounts receivable decreased by 83.52% to CNY 3,040,000.00, primarily due to the maturity of receivable notes[12] - Prepayments increased by 92.00% to CNY 146,390,000.00, driven by advance payments for project progress[13] - Total current assets decreased to CNY 366,186,011.14 from CNY 386,117,935.50, a decline of 5.2%[30] - Total liabilities decreased to CNY 207,092,634.85 from CNY 229,010,521.51, a reduction of 9.5%[31] - Total assets decreased to CNY 619,725,721.02 from CNY 642,429,021.13, a decline of 3.5%[31] - Non-current assets totaled CNY 253,539,709.88, down from CNY 256,311,085.63, a decrease of 1.1%[30] Cash Flow - Cash received from investment recoveries amounted to 80,000,000 CNY, primarily from the redemption of financial products and structured deposits[17] - Cash received from investment income was 866,200 CNY, mainly from the redemption of financial products and structured deposits[17] - Cash received from borrowings was 10,000,000 CNY, with no bank borrowings in the previous period[20] - Cash paid for debt repayment was 0 CNY, a decrease of 71,162,400 CNY compared to the previous period, as there were no such transactions this period[20] - The company generated 44,604,612.19 RMB in cash inflows from operating activities, down 13.5% from 51,503,553.62 RMB in the previous year[38] - Cash outflows for operating activities totaled 80,279,252.78 RMB, a decrease of 5.5% compared to 84,927,144.52 RMB in the previous year[38] - The company’s financing activities resulted in a net cash inflow of 9,172,412.81 RMB, contrasting sharply with a net outflow of -74,280,308.84 RMB in Q1 2017[39] Expenses - Operating costs increased by 32.23% to CNY 218,180,000.00, attributed to a higher proportion of overall solution products and purchased hardware[15] - Management expenses rose by 33.92% to CNY 632,270,000.00, mainly due to increased R&D expenses, employee salaries, and depreciation[16] - Tax expenses for the period were -69,400 CNY, significantly lower than the previous period, mainly due to deferred tax expenses from bad debt provisions[17] - Cash paid for purchasing goods and services decreased by 8,533,300 CNY, a reduction of 30.55%, due to lower procurement payments compared to the previous period[17] Shareholder Information - The total number of shareholders reached 6,321, with the top ten shareholders holding a significant portion of shares[10] Other Income - Other income increased by 8,020,500 CNY, mainly due to the implementation of new government subsidy standards, which classified government subsidies related to daily activities under other income[17] - Non-operating income decreased by 5,475,500 CNY, a decline of 91.97%, due to the reclassification of government subsidies to other income[17]

Financial Performance - The company's operating revenue for 2017 was CNY 268.68 million, an increase of 11.65% compared to CNY 240.64 million in 2016 [23]. - The net profit attributable to shareholders for 2017 was CNY 51.11 million, representing a growth of 13.06% from CNY 45.21 million in 2016 [23]. - The total profit reached 55.52 million yuan, with a year-on-year increase of 12.77% [58]. - The net profit attributable to shareholders reached 51.11 million yuan, marking a 13.06% increase from the prior year [61]. - The basic earnings per share for 2017 was CNY 0.64, down 14.67% from CNY 0.75 in 2016 [24]. - The company reported a significant decrease in cash inflow from operating activities, which fell by CNY 19.33 million compared to 2016, primarily due to lower cash received from sales [25]. - The net cash flow from operating activities decreased significantly to -CNY 6.16 million in 2017, down 118.92% from CNY 32.56 million in 2016 [23]. - The company achieved a 98.87% increase in revenue from operation services, totaling 585,258.93 [71]. - The company reported a total of 4,888,796.35 in revenue, representing a 20.20% increase compared to the previous year [71]. Dividend and Share Capital - The company plans to distribute a cash dividend of 1.90 CNY per 10 shares, totaling 15,375,294.00 CNY (including tax) to shareholders, with retained earnings of 147,280,987.65 CNY carried forward to future years [5]. - The total share capital of the company is 80,922,600 shares, which serves as the basis for the dividend distribution plan [5]. - The company reduced its registered capital from 80.9293 million CNY to 80.9226 million CNY following the repurchase and cancellation of restricted shares [163]. - The total number of restricted shares repurchased and canceled was 6,700 shares, which were held by six former employees [163]. - The total number of ordinary shares increased from 80,000,000 to 80,922,600, reflecting a change of 922,600 shares [185]. Audit and Compliance - The company has issued a standard unqualified audit report for the fiscal year, ensuring the accuracy and completeness of the financial report [4]. - The company did not report any issues regarding the integrity of its controlling shareholders or actual controllers during the reporting period [160]. - There were no significant litigation or arbitration matters reported for the year [159]. - The company did not face any risks of suspension or termination of listing during the reporting period [159]. - The company has not reported any significant related party debts or guarantees during the reporting period [166]. Research and Development - Research and development expenses rose to 47.83 million yuan, a 35.77% increase compared to the previous year [63]. - The company launched the "HearVai" AI project focused on acute cardiovascular diseases, aiming to develop precise diagnostic models [60]. - The company filed 58 patents during the reporting period, including 28 invention patents and 20 utility model patents [60]. - The company aims to increase R&D investment in artificial intelligence, with projects including an anesthesia management robot and an intelligent warning system for critical patients [6]. - The company is committed to continuous innovation in medical technology, as evidenced by its extensive patent and software copyright portfolio [84]. Market Position and Strategy - The company has established a leading market position in the clinical informationization sector, with its DoCare series and Doricon digital operating room solutions implemented in over 1,300 medical institutions across 32 provinces in China [102]. - The company aims to achieve smart healthcare by integrating various medical devices and information systems, enhancing clinical decision-making through data analysis and mining [34]. - The company is focusing on expanding its digital operating room solutions and promoting digital ward and emergency rescue platform solutions [33]. - The company aims to leverage its existing market share and customer base to enhance the application of current products and promote new products, thereby increasing its competitive advantage [103]. - The company recognizes the increasing competition in the health technology market, with non-traditional healthcare companies entering the space [103]. Financial Management - The company reported a significant increase in other current assets, primarily due to structured deposits and bank wealth management products totaling approximately 90 million yuan [93]. - The company’s cash management strategy focuses on maintaining the safety and liquidity of funds while ensuring the normal operation of its main business [169]. - The company redeemed a total of 23,000,000 from the entrusted financial product in 2017, yielding a total return of 254,876.72 [178]. - The company has a plan for future wealth management investments, ensuring compliance with legal procedures [170]. - The company reported a total of 5,000,000.00 in self-owned currency entrusted management with an annualized return of 3.50% [174]. Governance and Management - The company has a comprehensive governance structure in place, with all board members present at the board meeting [8]. - The company will implement a committee system in 2018 to enhance internal management and decision-making processes [8]. - The company aims to enhance employee engagement through improved compensation, training, and recruitment strategies to boost overall service efficiency and competitiveness [130]. - The company is committed to enhancing its technological capabilities and product offerings in response to evolving market demands and regulatory changes [104]. - The company has modified its profit distribution policy, including cash dividend policies, to protect the interests of minority investors [152]. Risks and Challenges - The company emphasizes the importance of investor awareness regarding the uncertainties in forward-looking statements and potential investment risks [6]. - The company faces risks related to accounts receivable, particularly if major clients experience financial difficulties or if collection measures are ineffective, which could adversely affect financial performance [131]. - The company has identified risks associated with seasonal fluctuations in business operations, which can lead to volatility in revenue and profit margins [132]. - The company acknowledges the potential impact of technology leakage or infringement on its competitive advantage [135]. - The company’s comprehensive gross profit margin has decreased during the reporting period, which, along with high expense ratios, directly affects operating profit levels [136].

Financial Performance - Operating revenue increased by 14.44% to CNY 166,600,031.89 for the first nine months of the year[6] - Net profit attributable to shareholders increased by 35.26% to CNY 29,259,530.39 for the first nine months of the year[6] - Total operating revenue for Q3 2017 was CNY 61,781,770.47, an increase of 14.8% compared to CNY 54,188,986.45 in Q3 2016[29] - Net profit for Q3 2017 reached CNY 15,579,365.46, representing a 38.8% increase from CNY 11,277,413.33 in Q3 2016[30] - Net profit for the first nine months of 2017 reached CNY 28,429,207.93, up 45.3% from CNY 19,575,084.65 in the same period last year[32] - The company reported a total profit of CNY 14,987,971.03 for Q3 2017, an increase of 12.9% from CNY 13,267,673.77 in Q3 2016[32] Cash Flow - Cash flow from operating activities showed a negative net amount of CNY -51,170,428.66, compared to CNY -25,842,352.75 in the same period last year[6] - The net cash flow from operating activities for the first nine months of 2017 was negative CNY 51,170,428.66, worsening from negative CNY 25,842,352.75 in the same period last year[35] - Net cash flow from operating activities for Q3 2017 was -CNY 51,192,672.85, compared to -CNY 20,100,793.97 in Q3 2016, indicating a decline[38] - Cash received from sales of goods and services for the first nine months of 2017 was CNY 144,105,287.49, compared to CNY 132,383,252.54 in the same period last year[37] - Cash inflow from investment activities in Q3 2017 totaled CNY 131,179,907.24, a significant increase from CNY 298,023.10 in Q3 2016[38] Assets and Liabilities - Total assets decreased by 15.26% to CNY 585,004,085.06 compared to the end of the previous year[6] - The total assets as of September 30, 2017, were RMB 585 million, down from RMB 690 million at the beginning of the year[21] - The total liabilities decreased from RMB 295 million to RMB 174.77 million during the same period[22] - Current liabilities totaled CNY 204,413,801.51, down from CNY 244,831,746.66 in the previous year, indicating a reduction of 16.5%[26] - The total liabilities decreased to CNY 208,417,756.31 from CNY 324,881,539.26, showing a significant reduction of 35.9%[26] Equity and Shareholder Information - The number of shareholders reached 7,738 at the end of the reporting period[9] - The company's total equity increased from RMB 394.97 million to RMB 410.23 million, reflecting a positive growth in retained earnings[22] - The company's total equity increased to CNY 387,929,897.19 from CNY 373,500,689.24, marking a growth of 3.9%[26] Expenses - Management expenses rose by RMB 19.97 million, a 46.29% increase, mainly attributed to higher R&D costs, employee salaries, and depreciation[13] - Financial expenses increased by RMB 1.20 million, a significant growth of 190.81%, mainly due to interest from long-term loans after the headquarters building became operational[13] - Sales expenses for the first nine months of 2017 were CNY 50,356,959.68, up 7.1% from CNY 46,692,856.73 in the same period last year[31] - The company’s financial expenses for the first nine months of 2017 were CNY 1,831,363.99, significantly higher than CNY 636,662.52 in the same period last year[31] Inventory and Prepaid Accounts - Inventory increased by 41.94% to CNY 610,250.00, primarily due to project stocking and costs of unfinished projects[11] - Prepaid accounts increased by 196.71% to CNY 998,200.00, mainly for advancing procurement payments[11] Other Financial Metrics - The weighted average return on equity decreased by 3.71 percentage points to 7.25%[7] - The company reported a basic and diluted earnings per share of CNY 0.36, unchanged from the previous year[7] - The gross profit margin for Q3 2017 was approximately 11.8%, compared to 10.4% in Q3 2016, indicating improved profitability[29] - Research and development expenses were CNY 24,418,330.98 for Q3 2017, up from CNY 17,773,471.32 in the same quarter last year, reflecting a 37.2% increase[29]

Financial Performance - The company's operating revenue for the first half of 2017 was ¥104,818,261.42, representing a 14.70% increase compared to ¥91,386,888.06 in the same period last year [22]. - The net profit attributable to shareholders for the first half of 2017 was ¥13,680,164.93, a 32.11% increase from ¥10,354,755.74 in the previous year [22]. - The net cash flow from operating activities for the first half of 2017 was -¥46,291,122.56, compared to -¥20,815,588.02 in the same period last year, indicating a worsening cash flow situation [22]. - The total assets at the end of the reporting period were ¥562,988,374.87, down 18.45% from ¥690,343,149.99 at the end of the previous year [22]. - The basic earnings per share for the first half of 2017 remained unchanged at ¥0.17 compared to the same period last year [23]. - The weighted average return on net assets decreased to 3.42% from 5.40% in the previous year, a decline of 1.98 percentage points [23]. Corporate Governance - The financial report has been declared true, accurate, and complete by the responsible persons [4]. - The report is unaudited, and the board of directors has ensured its integrity [4]. - The company held two shareholder meetings during the reporting period, complying with legal and regulatory requirements [72]. - The company has committed to not transferring or entrusting the management of its shares for 36 months from the date of listing [75]. - The company will announce any intended share reductions 3 trading days in advance [78]. - The company has established a mechanism to reclaim any illegal proceeds from share reductions through cash dividends [78]. Risk Factors - The company has detailed risk factors in the report, which investors should review [7]. - The company faces risks related to large accounts receivable, which could impact financial performance if major clients' financial conditions deteriorate [65]. - Seasonal fluctuations in business operations may lead to lower net profits in the first two quarters of the year, affecting overall financial performance [66]. - The company has not experienced any technology leaks or infringements during the reporting period, but such risks remain a concern for future operations [68]. Market Position and Strategy - The company focuses on clinical medical management information systems and overall solutions, aiming to enhance healthcare quality and efficiency through digitalization [28]. - The company has established a customer service system covering over 1,100 medical institutions across 32 provinces, including more than 400 tertiary hospitals [30]. - The company has developed a broad-spectrum medical device data collection platform and medical information integration platform, laying a technological foundation for future product expansion [46]. - The company aims to enhance its research and development efforts to innovate new products and technologies in the medical field [152]. - The company is focused on strategic partnerships and potential acquisitions to bolster its market position and operational capabilities [152]. Stock Incentive Plan - The company approved a stock option and restricted stock incentive plan on March 25, 2017, to motivate employees [84]. - The company granted 929,300 stock options with an exercise price of 60.68 CNY per share and 929,300 restricted shares at a grant price of 30.25 CNY per share as part of the 2017 equity incentive plan [87]. - The total cost for the stock options granted is approximately 4,997,700 CNY, with annual allocations of 994,100 CNY, 1,972,100 CNY, 1,504,800 CNY, and 526,700 CNY from 2017 to 2020 [88]. - The company completed the first grant of 929,300 stock options and restricted stocks on June 7, 2017, with an exercise price of RMB 60.68 per share and a grant price of RMB 30.25 per share [98]. Financial Management - The company reported a significant decrease in short-term borrowings by 59.85% to 21 million RMB, indicating improved financial management [58]. - The company’s cash and cash equivalents decreased by 63.99% to 103.63 million RMB, influenced by loan repayments and investments in financial products [59]. - The company reported a decrease in cash and cash equivalents from ¥287,781,948.97 to ¥103,629,657.53, representing a decline of approximately 64% [124]. - The company reported a total comprehensive income of CNY 12,900,552.86 for the first half of 2017, up from CNY 6,533,103.83 in the same period last year, reflecting strong overall performance [135]. Subsidiaries and Shareholding - The company has two wholly-owned subsidiaries, with total assets of CNY 44.446 million and net assets of CNY 41.287 million for Mediston (Beijing) Medical Technology Co., Ltd. [62]. - The other subsidiary, Shanghai Mediston Medical Technology Co., Ltd., reported total assets of CNY 0.6246 million and net assets of CNY -CNY 6.9115 million [63]. - The company has not disclosed any significant changes in shareholding structure or other relevant information during the reporting period [99]. - The company confirmed that there are no related party relationships among the major shareholders listed, except for a minor holding by Mr. Weng Kang [107]. Accounting and Financial Reporting - The company adheres to the Chinese Accounting Standards, ensuring that financial reports accurately reflect its financial status and operational results [164]. - The company’s financial statements are prepared based on the going concern principle, indicating a sustainable operational capacity for at least 12 months from the reporting date [163]. - The company’s accounting currency is RMB, which is used for all financial reporting [167]. - The company follows specific accounting treatments for business combinations, distinguishing between same-control and non-same-control mergers [170].

2017 年第一季度报告 公司代码：603990 公司简称：麦迪科技 苏州麦迪斯顿医疗科技股份有限公司 2017 年第一季度报告 1 / 18 | 一、 | 重要提示 | 3 | | --- | --- | --- | | 二、 | 公司基本情况 | 3 | | 三、 | 重要事项 | 5 | | 四、 | 附录 | 8 | 2017 年第一季度报告 一、 重要提示 1.1 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整， 不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和连带的法律责任。 1.2 公司全体董事出席董事会审议季度报告。 1.3 公司负责人翁康、主管会计工作负责人吴旺盛及会计机构负责人（会计主管人员）冯敏保证 季度报告中财务报表的真实、准确、完整。 1.4 本公司第一季度报告未经审计。 二、 公司基本情况 2.1 主要财务数据 单位：元 币种：人民币 | | 本报告期末 | 上年度末 | 本报告期末比上年度末增 | | --- | --- | --- | --- | | | | | 减(%) | | 总资产 | 578,133,711.35 | 690,343, ...

Dividend Distribution - The company plans to distribute a cash dividend of 1.75 CNY per 10 shares, totaling 14,000,000 CNY for all shareholders[2]. - The total share capital for the dividend distribution is based on 80,000,000 shares[2]. - In 2016, the company distributed cash dividends amounting to 1.75 RMB per 10 shares, with a total cash dividend of 14,000,000 RMB, representing 30.97% of the net profit attributable to ordinary shareholders[125]. - The company has a cash dividend policy that mandates a minimum of 20% of distributable profits to be paid out as cash dividends when conditions are met[123]. Financial Performance - In 2016, the company reported a revenue of RMB 240,643,007.43, representing a 19.21% increase compared to RMB 201,871,275.48 in 2015[18]. - The net profit attributable to shareholders was RMB 45,205,718.82, up 16.04% from RMB 38,955,976.64 in the previous year[18]. - The company's total assets increased by 58.58% to RMB 690,343,149.99 at the end of 2016, compared to RMB 435,336,908.76 at the end of 2015[18]. - The company's net assets attributable to shareholders rose by 111.63% to RMB 394,970,957.82 from RMB 186,634,584.26 in 2015[18]. - The weighted average return on equity was 21.60% in 2016, down from 23.31% in 2015[19]. - The company achieved operating revenue of CNY 240.64 million, a year-on-year increase of 19.21%[61]. - The total profit reached CNY 49.23 million, reflecting a growth of 8.09% compared to the previous year[61]. - Net profit attributable to shareholders was CNY 45.21 million, up 16.04% year-on-year[61]. Operational Efficiency - The net cash flow from operating activities decreased by 13.26% to RMB 32,558,391.51 from RMB 37,536,097.88 in 2015[18]. - The company generated a cash flow from operating activities of -¥32,786,913.5 in Q1 2016, which improved to ¥58,400,744.26 in Q4 2016, reflecting better operational efficiency[21]. - The company's operating cash flow decreased by 13.26% to CNY 32.56 million, reflecting changes in operational efficiency[66]. Market Position and Growth - By the end of 2016, the company had over 1,000 medical institution clients across 32 provinces in China, including more than 400 top-tier hospitals, demonstrating its market penetration[26]. - The company is positioned within the medical informationization sector, which is experiencing rapid growth due to ongoing healthcare reforms in China[45]. - The company has established a leading market position in clinical information technology, with its products applied in over 1,000 medical institutions across 32 provinces[102]. - The company is positioned to benefit from the significant growth potential in China's healthcare information technology sector, driven by increasing healthcare expenditures and government policies promoting health IT[47]. Research and Development - The company’s R&D expenditure rose by 75.65% to CNY 35.23 million, indicating a strong focus on innovation[66]. - The company has received 11 patent applications during the reporting period, including 5 invention patents[63]. - The company has applied for and obtained 40 software copyrights during the reporting period[87]. - The company is currently developing a digital operating room solution and a digital intensive care unit solution[84]. - The company plans to increase research and development investments in medical big data and artificial intelligence, enhancing its technological capabilities in the healthcare sector[111]. Risk Management - The company has provided a detailed description of major risks related to its operations in the report[4]. - The report includes a forward-looking statement risk declaration, highlighting uncertainties in future plans[3]. - The audit report issued by Zhonghui Accounting Firm is a standard unqualified opinion[4]. Governance and Compliance - The company has maintained a governance structure that ensures clear responsibilities and effective checks and balances among shareholders, the board, and management[182]. - The company did not report any significant differences from the requirements set by the China Securities Regulatory Commission regarding corporate governance[182]. - There were no significant lawsuits or arbitration matters during the reporting period[141]. - The company has not disclosed any major related party transactions during the reporting period[142]. Shareholder Information - The total number of ordinary shares increased from 60,000,000 to 80,000,000, with the proportion of unrestricted circulating shares being 25%[149]. - The company successfully completed a public offering of 20,000,000 shares at a price of RMB 9.69 per share, raising a total of RMB 193.8 million[151]. - The number of ordinary shareholders increased from 9,061 to 12,724 during the reporting period, indicating a significant rise in public interest[156]. - The largest shareholder, Weng Kang, holds 19,728,000 shares, representing 24.66% of the total shares[158]. Employee Information - The total number of employees in the parent company is 511, with a combined total of 643 employees across the parent and major subsidiaries[177]. - The company has 374 employees in research and technical services, 183 in sales, and 83 in management[177]. - The total remuneration for directors, supervisors, and senior management during the reporting period is 3.8066 million yuan[175]. Financial Position - Total assets increased to RMB 690,343,149.99, up from RMB 435,336,908.76, representing a growth of approximately 58.6% year-over-year[196]. - Current assets rose to RMB 460,506,546.32, compared to RMB 252,079,590.54, marking an increase of about 82.6%[196]. - Cash and cash equivalents significantly increased to RMB 287,781,948.97 from RMB 115,496,033.47, reflecting a growth of approximately 149.5%[195]. - Total liabilities amounted to RMB 295,372,192.17, up from RMB 248,702,324.50, indicating an increase of around 18.7%[196].